The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Open accessAbstract
BACKGROUNDOsimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKIsensitizing and EGFR T790M resistance mutations.A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).Data from the final analysis of overall survival have not been reported. METHODSIn this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).Overall survival was a secondary end point. RESULTSThe median overall survival was 38.6 months (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 months and 11.5 months, respectively.Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. CONCLUSIONSAmong patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.(Funded by AstraZeneca; FLAURA ClinicalTrials.govnumber, NCT02296125.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second- and third-generation TKIs have shown significantly longer PFS compared with first-generation TKIs, and the third-generation TKI, osimertinib, has shown superior OS compared with first-generation TKIs.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“in the recent FLAURA head-to-head trial, first-line treatment with osimertinib led to superior PFS and OS compared with a first-generation TKI (gefitinib or erlotinib).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [11]
In the citing paper
“In the first line setting, EGFR-tyrosine kinase inhibitors have shown efficacy, particularly with osimertinib. 21 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Self-citationAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,003
Lü, S., Casarini, I., Kato, T., Cobo, M., Özgüroğlu, M., Hodge, R. A., van der Gronde, T., Saggese, M., & Ramalingam, S. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.004 · Cited by 64
Self-citationZhao, Y., Li, S., Yang, X., Chu, L., Wang, S., Tong, T., Chu, X., Yu, F., Zeng, Y., Guo, T., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33904 · Cited by 64
Spinal metastasis: narrative reviews of the current evidence and treatment modalities
Jaipanya, P., & Chanplakorn, P. (2022) · Journal of International Medical Research · doi:10.1177/03000605221091665 · Cited by 64
Mok, T. S. K., Janne, P. A., Nishio, M., Novello, S., Reck, M., Steuer, C. E., Wu, Y.-L., Fougeray, R., Fan, P., Meng, J., et al. (2023) · Future Oncology · doi:10.2217/fon-2023-0602 · Cited by 68
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
Nakamura, Y., Ozaki, H., Ueno, M., Komatsu, Y., Yuki, S., Esaki, T., Taniguchi, H., Sunakawa, Y., Yamaguchi, K., Kato, K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03244-8 · Cited by 66
Li, X.-M., Li, W., Lin, J., Yan, H., Tu, H., Chen, H., Wang, B.-C., Wang, Z., Zhou, Q. H., Zhang, X., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.001 · Cited by 63
Park, S., Baldry, R., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Kim, Y. J., Lee, Y., Kim, D., Kim, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00708 · Cited by 63
Self-citationLung Cancer: Targeted Therapy in 2025
Bouchard, N., & Daaboul, N. (2025) · Current Oncology · doi:10.3390/curroncol32030146 · Cited by 64
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3819 · Cited by 62
Zhao, Y., Cheng, B., Chen, Z., Li, J., Liang, H., Chen, Y., Zhu, F., Li, C., Xu, K., Xiong, S., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103305 · Cited by 65
Ferlenghi, F., Scalvini, L., Vacondio, F., Castelli, R., Bozza, N., Marseglia, G., Rivara, S., Lodola, A., Monica, S. L., Minari, R., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113786 · Cited by 63
Self-citationOverall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
Hayashi, H., Nadal, E., Gray, J. E., Ardizzoni, A., Caria, N., Puri, T., & Grohé, C. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.009 · Cited by 63
Self-citationAdvances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Ma, H., Das, J. P., Prendergast, C. M., de Jong, D., Braumuller, B., Paily, J., Huang, S., Liou, C., Giarratana, A. O., Hosseini, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110566 · Cited by 61
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02744 · Cited by 64
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60
Abuhelwa, Z., Alloghbi, A., & Nagasaka, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102393 · Cited by 62
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Murphy, R., Halford, S. E. R., & Symeonides, S. N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144056 · Cited by 59
Middleton, G., Robbins, H. L., André, F., & Swanton, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.004 · Cited by 59
Wilding, B., Scharn, D., Böse, D., Baum, A., Santoro, V., Chetta, P., Schnitzer, R., Botesteanu, D., Reiser, C., Kornigg, S., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00412-y · Cited by 60
Sun, H., Li, M., Huang, W., Zhang, J., Wei, S., Yang, Y., Wang, Z., Ye, S., Gong, H., Zhang, Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02075 · Cited by 63
Xing, L., Wu, G., Wang, L., Li, J., Wang, J., Yuan, Z., Chen, M., Xu, Y., Fu, X., Zhu, Z., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.026 · Cited by 58
Saw, S. P. L., Zhou, S., Chen, J., Lai, G. G. Y., Ang, M., Chua, K. L. M., Kanesvaran, R., Ng, Q. S., Jain, A., Tan, W. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.31892 · Cited by 57
Cortot, A. B., Le, X., Smit, E. F., Viteri, S., Kato, T., Sakai, H., Park, K., Camidge, D. R., Berghoff, K., Vlassak, S., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.01.003 · Cited by 57
Gijtenbeek, R. G. P., Damhuis, R. A. M., van der Wekken, A. J., Hendriks, L. E. L., Groen, H. J. M., & van Geffen, W. H. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100592 · Cited by 57
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
Kobayashi, Y., Chhoeu, C., Li, J., Price, K. S., Kiedrowski, L. A., Hutchins, J. L., Hardin, A. I., Wei, Z., Hong, F., Bahcall, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04451-4 · Cited by 56
Wan, X., Xie, B., Sun, H., Gu, W., Wang, C., Deng, Q., & Zhou, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02509-x · Cited by 56
Update on the Management of Brain Metastasis
Singh, K., Saxena, S., Khosla, A. A., McDermott, M. W., Kotecha, R. R., & Ahluwalia, M. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01312-w · Cited by 56
Hou, X., Li, M., Wu, G., Feng, W., Su, J., Jiang, H., Jiang, G., Chen, J., Zhang, B., You, Z., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55050 · Cited by 56
Le, X., Patel, J. D., Shum, E., Baik, C. S., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R. D., Elamin, Y. Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00533 · Cited by 56
Self-citationBurns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 58
Self-citationImplications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies
Brown, S., Lavery, J. A., Shen, R., Martin, A. S., Kehl, K. L., Sweeney, S. M., Lepisto, E. M., Rizvi, H. A., McCarthy, C. G., Schultz, N. D., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5153 · Cited by 55
Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00337-w · Cited by 57
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Haratake, N., Ozawa, H., Morimoto, Y., Yamashita, N., Daimon, T., Bhattacharya, A., Wang, K., Nakashoji, A., Isozaki, H., Shimokawa, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.017 · Cited by 54
Leonetti, A., Verzè, M., Minari, R., Perrone, F., Gnetti, L., Bordi, P., Pluchino, M., Nizzoli, R., Azzoni, C., Bottarelli, L., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02475-9 · Cited by 54
Self-citationLung Cancer in Nonsmoking Individuals
Murphy, C., Pandya, T., Swanton, C., & Solomon, B. (2025) · JAMA · doi:10.1001/jama.2025.17695 · Cited by 55
Qin, Q., Li, X., Liang, X., Zeng, L., Wang, J., Sun, L., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13521 · Cited by 55
Wang, Y., Jiang, M., Zhu, J., Qu, J., Qin, K., Zhao, D., Wang, L., Dong, L., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110797 · Cited by 54
Su, W., Wang, L., Zhao, H., Hu, S., Zhou, Y., Guo, C., Wu, B., Li, L., Yang, Z., Beer, D. G., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.025 · Cited by 54
Ntzifa, A., Strati, A. D., Kallergi, G., Kotsakis, A. P., Georgoulias, V., & Lianidou, E. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82068-9 · Cited by 54
Liang, S., Hsu, C.-C., Song, H., Huang, Y.-C., Kuo, C.-W., Yao, X., Li, C., Yang, H.-C., Hung, Y.-L., Chao, S.-Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01895-2 · Cited by 54
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 56
van Rosenburgh, I. K. V. A., Lu, D. M., Grant, M. J., Stayrook, S. E., Phadke, M. A., Walther, Z., Goldberg, S. B., Politi, K. A., Lemmon, M. A., Ashtekar, K. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34398-z · Cited by 53
Attili, I., Corvaja, C., Spitaleri, G., Signore, E. D., Aliaga, P. T., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15205079 · Cited by 56
Liu, H. E., Vuppalapaty, M., Wilkerson, C. L., Renier, C. M., Chiu, M., Lemaire, C. A., Che, J., Matsumoto, M. M., Carroll, J., Crouse, S. C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572895 · Cited by 53
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
Yan, D., Huelse, J. M., Kireev, D., Tan, Z., Chen, L., Goyal, S., Wang, X., Frye, S. V., Behera, M., Schneider, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150517 · Cited by 53
Self-citationNovel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
de Jong, D., Das, J. P., Ma, H., Valiplackal, J. P., Prendergast, C. M., Roa, T., Braumuller, B., Deng, A., Dercle, L., Yeh, R., et al. (2023) · Cancers · doi:10.3390/cancers15102855 · Cited by 55
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy
Bianchi, A. S., Pizzutilo, E. G., Marrapese, G., Tosi, F., Cerea, G., & Siena, S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1747439 · Cited by 52
Zhao, P., Zhang, J., Wu, A., Zhang, M., Zhao, Y., Tang, Y., Wang, B., Chen, T., Li, F., Zhao, Q., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.052 · Cited by 52
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Li, X., Chen, C., Wang, Z., Liu, J., Sun, W., Shen, K., Lv, Y., Zhu, S., Zhan, P., Lv, T., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02075-8 · Cited by 52
Fang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., et al. (2025) · BMJ · doi:10.1136/bmj-2025-085680 · Cited by 51
“21 22 23-25 Options for patients with treatment failure after both EGFR-tyrosine kinase inhibitors and platinum based chemotherapy become increasingly restricted.”
Lai-Kwon, J. E., Heynemann, S., Flore, J., Dhillon, H. M., Duffy, M., Burke, J. M., Briggs, L., Leigh, L., Mileshkin, L., Solomon, B., et al. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01024-8 · Cited by 51
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
Wu, C., Yu, D., Sun, S., & Li, F. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.018 · Cited by 51
Yu, H. A., Paz-Ares, L. G., Yang, J. C., Lee, K. H., Garrido, P., Park, K., Kim, J.-H., Lee, K. H., Mao, H., Wijayawardana, S. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1690 · Cited by 50
Self-citationKinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Naik, R. R., Shakya, A. K., Aladwan, S., & El‐Tanani, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806568 · Cited by 50
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Gen, S., Tanaka, I., Morise, M., Koyama, J., Kodama, Y., Matsui, A., Miyazawa, A., Hase, T., Hibino, Y., Yokoyama, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09741-8 · Cited by 50
Oligometastasis: Past, Present, Future
Gutiontov, S. I., Pitroda, S. P., & Weichselbaum, R. R. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.02.019 · Cited by 50
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D. E., Stratmann, J., Riedel, R. F., Schaefer, M., Alt, J. A., Gutz, S., Christoph, D. C., Laack, E., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920980558 · Cited by 49
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
Césaire, M., Montanari, J., Curcio, H., Lerouge, D., Gervais, R., Demontrond, P., Balosso, J., & Chevalier, F. (2022) · Cancers · doi:10.3390/cancers14122829 · Cited by 49
Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research
Bollhagen, A., & Bodenmiller, B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1165 · Cited by 55
Passarelli, A. M., Aieta, M., Sgambato, A., & Gridelli, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01479 · Cited by 50
Benoit, L., Mir, O., Vialard, F., & Berveiller, P. (2021) · Cancers · doi:10.3390/cancers13061238 · Cited by 49
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Bertino, E. M., Gentzler, R. D., Clifford, S. E., Kolesar, J., Muzikansky, A., Haura, E. B., Piotrowska, Z., Camidge, D. R., Stinchcombe, T. E., Hann, C. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4084 · Cited by 48
Targeted therapeutic options in early and metastatic NSCLC-overview
Gálffy, G., Mórocz, É., Korompay, R., Hécz, R., Bujdosó, R., Puskás, R., Lovas, T., Gáspár, E., Yahya, K., Király, P. A., et al. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611715 · Cited by 55
Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024) · Genes · doi:10.3390/genes15040468 · Cited by 49
Horinouchi, H., Cho, B. C., Camidge, D. R., Goto, K., Tomasini, P., Li, Y., Vasilopoulos, A., Brunsdon, P., Hoffman, D., Shi, W., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.001 · Cited by 49
Self-citationFloc’h, N., Lim, S., Bickerton, S., Ahmed, A., Orme, J. P., Urosevic, J., Martin, M. J., Cross, D. A. E., Cho, B. C., & Smith, P. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0103 · Cited by 48
Self-citationUchiyama, A. A. T., Silva, P. A. I. A., Lopes, M. S. M., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimenta, J. R., Machado, L. M., Shimba, D. S., & Peixoto, R. D. (2021) · Current Oncology · doi:10.3390/curroncol28010076 · Cited by 48
Aumolertinib: A Review in Non-Small Cell Lung Cancer
Shirley, M., & Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01695-2 · Cited by 49
Sato, Y., Sumikawa, H., Shibaki, R., Morimoto, T., Sakata, Y., Oya, Y., Tamiya, M., Suzuki, H., Matsumoto, H., Yokoi, T., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.05.035 · Cited by 47
Yu, X., Cheng, M., Lu, K. J., Shen, Y., Zhong, Y., Liu, J., Xiong, Y., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00345 · Cited by 47
Bertoli, E., Carlo, E. D., Conte, A. D., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136936 · Cited by 48
Yang, J., Li, Y., Sun, J., Zou, H., Sun, Y., Luo, J., Xie, Q., Rong, A., Wang, H., Li, X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04159 · Cited by 47
Obst-Sander, U., Ricci, A., Kuhn, B., Friess, T., Koldewey, P., Kuglstatter, A., Hewings, D. S., Goergler, A., Steiner, S., Rueher, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00893 · Cited by 47
Ismail, M. A., Abusaif, M. S., El-Gaby, M. S. A., Ammar, Y. A., & Ragab, A. (2023) · RSC Advances · doi:10.1039/d3ra01635h · Cited by 47
Du, Z., Kan, H., Sun, J., Liu, Y., Gu, J., Akemujiang, S., Zou, Y., Jiang, L., Wang, Q., Li, C., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101266 · Cited by 47
Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives
Kapoor, D. U., Gandhi, S. M., Swarn, S., Lal, B., Prajapati, B. G., Khondee, S., Mangmool, S., Singh, S. K., & Chittasupho, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091091 · Cited by 48
Stares, M. D., Swan, A. M., Cumming, K., Ding, T.-E., Leach, J., Stratton, C., Thomson, F., Barrie, C., Maclennan, K., Campbell, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734735 · Cited by 47
Improving the tolerability of osimertinib by identifying its toxic limit
Agema, B. C., Veerman, G., Steendam, C. M. J., Lanser, D. A. C., Preijers, T., van der Leest, C., Koch, B. C. P., Dingemans, A. C., Mathijssen, R. H. J., & Koolen, S. L. W. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221103212 · Cited by 47
Li, W., & Cui, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03296-6 · Cited by 47
Teng, Y.-M., Wu, K., & Xu, D. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.668774 · Cited by 50
Shah, M. P., & Neal, J. W. (2022) · Drugs · doi:10.1007/s40265-022-01698-z · Cited by 47
Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Pan, Q., Lu, Y., Li, X., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00792 · Cited by 48
EGFR trafficking: effect of dimerization, dynamics, and mutation
Schultz, D. F., Billadeau, D. D., & Jois, S. D. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258371 · Cited by 48
Monica, S. L., Fumarola, C., Cretella, D., Bonelli, M. A., Minari, R., Cavazzoni, A., Digiacomo, G., Galetti, M., Volta, F., Mancini, M., et al. (2020) · Cancers · doi:10.3390/cancers13010006 · Cited by 46
Self-citationDiving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Sorolla, M. A., Sorolla, A., Parisi, E., Salud, A., & Porcel, J. M. (2021) · Cancers · doi:10.3390/cancers13112798 · Cited by 46
Li, X., Wang, Y., Li, X., Feng, G., Hu, S., & Bai, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638763 · Cited by 46
Hsu, K.-H., Tseng, J., Yang, T., Chen, K., Su, K., Yu, S., Chen, J. J. W., Huang, Y.-H., & Chang, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-13102-7 · Cited by 45
Zhang, C., Sun, H., Su, J., Chen, Y., Zhang, S., Zheng, M.-Y., Li, Y., Huang, J., Zhang, C., Tai, Z., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.016 · Cited by 45
The Role of Microglia in Brain Metastases: Mechanisms and Strategies
Feng, Y., Hu, X., Zhang, Y., & Wang, Y. (2024) · Aging and Disease · doi:10.14336/ad.2023.0514 · Cited by 45
Kästner, A., Kron, A., van den Berg, N., Moon, K., Scheffler, M., Schillinger, G., Pelusi, N., Hartmann, N., Rieke, D. T., Stephan-Falkenau, S., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100788 · Cited by 45
Lu, Z., Cai, J., Wang, X., Wei, J., Zeng, Z., Huang, L., & Liu, A. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13738 · Cited by 46
Ito, K., Morise, M., Wakuda, K., Hataji, O., Shimokawaji, T., Takahashi, K., Furuya, N., Takeyama, Y., Gotô, Y., Abe, T., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100115 · Cited by 45
Metadata
- Authors
- Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M.-C., Imamura, F., Kurata, T., Todd, A., Hodge, R., Saggese, M., Rukazenkov, Y., & Soria, J.-C.
- Affiliations
- Université Paris-Sud (FR)
- From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.S.R.); the Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif (D.P., J.-C.S.), and University Paris Sud, Orsay (J.-C.S.) — both in France; the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul...
- ORCID
- Ramalingam, Suresh S.
- Vansteenkiste, Johan
- Planchard, David
- Cho, Byoung Chul
- Gray, Jhanelle E.
- Ohe, Yuichiro
- Zhou, Caicun
- Reungwetwattana, Thanyanan
- Cheng, Ying
- Shah, Riyaz
- Cobo, Manuel
- Lee, Ki Hyeong
- Cheema, Parneet
- Tiseo, Marcello
- John, Thomas
- Lin, Meng-Chih
- Imamura, Fumio
- Kurata, Takayasu
- Todd, Alexander
- Hodge, Rachel
- Soria, Jean-Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2990041408
- Cited by
- 2,914
- References
- 27
- Citations by year
- 2026: 354 · 2025: 462 · 2024: 487 · 2023: 411 · 2022: 480 · 2021: 434 · 2020: 284
- FWCI
- 222.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- AstraZeneca (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, gefitinib, erlotinib, first-line therapy, overall survival, exon 19 deletion, L858R mutation, T790M resistance, progression-free survival, adverse events, treatment duration
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Acrylamides, Aged, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Proportional Hazards Models, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
